Clear Str Downgrades Janux Therapeutics (NASDAQ:JANX) to Hold

Janux Therapeutics (NASDAQ:JANX) was downgraded by analysts at Clear Str from a “strong-buy” rating to a “hold” rating in a report released on Tuesday,Zacks.com reports.

Several other equities analysts have also recently weighed in on the company. Wedbush reiterated an “outperform” rating and set a $45.00 price objective (down previously from $76.00) on shares of Janux Therapeutics in a report on Tuesday, December 2nd. HC Wainwright lowered their price objective on shares of Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating for the company in a research report on Tuesday, December 2nd. Piper Sandler dropped their price objective on shares of Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating on the stock in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Wednesday, October 8th. Finally, Wolfe Research started coverage on Janux Therapeutics in a report on Tuesday, November 18th. They set a “peer perform” rating for the company. Eleven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $60.08.

Janux Therapeutics Stock Performance

JANX opened at $13.15 on Tuesday. The firm’s fifty day moving average is $19.10 and its two-hundred day moving average is $22.94. The firm has a market cap of $790.97 million, a PE ratio of -7.83 and a beta of 2.88. Janux Therapeutics has a twelve month low of $12.80 and a twelve month high of $47.58.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.21. The firm had revenue of $10.00 million during the quarter, compared to the consensus estimate of $3.07 million. Equities analysts forecast that Janux Therapeutics will post -1.38 EPS for the current fiscal year.

Insider Transactions at Janux Therapeutics

In related news, insider Thomas Diraimondo sold 2,505 shares of Janux Therapeutics stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $13.73, for a total value of $34,393.65. Following the sale, the insider owned 124,425 shares of the company’s stock, valued at approximately $1,708,355.25. The trade was a 1.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO David Alan Campbell sold 8,072 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $110,828.56. Following the transaction, the chief executive officer directly owned 284,982 shares of the company’s stock, valued at $3,912,802.86. This trade represents a 2.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 42,364 shares of company stock worth $972,185. 29.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Janux Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in JANX. Osaic Holdings Inc. raised its position in Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after acquiring an additional 3,037 shares in the last quarter. Virtus Investment Advisers LLC increased its stake in shares of Janux Therapeutics by 37.9% during the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after purchasing an additional 1,011 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Janux Therapeutics by 175.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after purchasing an additional 2,502 shares during the period. Ameritas Investment Partners Inc. lifted its stake in Janux Therapeutics by 25.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock valued at $93,000 after purchasing an additional 820 shares during the last quarter. Finally, Winthrop Capital Management LLC bought a new position in Janux Therapeutics during the third quarter worth about $106,000. 75.39% of the stock is owned by institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.